Bayer to develop and market Cytokinetics’ aficamten in Japan
Bayer will obtain rights to Cytokinetics’ aficamten in Japan, in exchange for around €70m in upfront and near-term payments, up to €490m in commercial milestone payments, along with tiered royalties...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry